Pharmanutra S.p.a. · MIL:PHN
Pharmanutra — Q3 2021 Earnings Presentation
19 slides from Pharmanutra's earnings presentation, Nov 1, 2021
Slide 1: Q3 2021 Financial Results
Q3_ 2021 FINANCIAL RESULTS @PHARMANUTRA
Slide 2: Disclaimer
2 DISCLAIMER This document has been prepared by Pharmanutra S.p.A. (the “Company”) for use during meetings with investors and financial analyst and is solely for information purposes. It contains solely data and information provided by the Company or already in the public domain. This Document may n
Slide 3: Group Presentation & Highlights 3Q
GROUP PRESENTATION & HIGHLIGHTS 3Q
Slide 4: Highlights Q3
4 HIGHLIGHTS Q3 • Solid top line momentum confirmed by 3Q results: the quarterly performance show exceptional results in terms of net sales growth ( + 47,2% respect 3Q 2020) and EBITDA margin (Euro 5,3 million compared to Euro 2,7 million in 3Q 2020); • Net Sales Revenues far above expectations: + 2
Slide 5: Highlights Q3
5 HIGHLIGHTS Q3 • Iron Market Leadership improved: as reported by FederSalus, based on August IQVIA data related to the food supplement market, SiderAL® Forte was again the top seller nutritional supplement in Italy, with a 16,9% increase compared to the same period last year; as at September 30 202
Slide 6: Economic and Financial Data
ECONOMIC AND FINANCIAL DATA
Slide 7: Highlights Q3 2021
7 HIGHLIGHTS Q3 2021 +21% +29% +32% €20,9 1,08 Mio POSITIVE EBITDA ADJUSTED NET RESULT EXCL. NON-RECURRING ITEMS NET FINANCIAL POSITION EPS NET REVENUES € 15,8 M € 10,4 M (€ +1,5 M COMPARED EXCL. NON-RECURRING ITEMS € 49,3 M (32,1% MARGIN ON NET REVENUES) (21,2% MARGIN ON NET REVENUES) TO 31/12 2020
Slide 8: Economic Results
8 ECONOMIC RESULTS EBITDA Adjusted and Net Result Adjusted on Net Revenues 3Q 2021 Ebitda Adjusted shows an higher marginality% compared to Q3 2020 due to the increase in revenues. 3Q 2020 Ebitda Adjusted is net of non-recurring items relating to a contractual indemnity (€ 1 million) and non-recurri
Slide 9: Profit and Loss
9 Profit and Loss REVENUES Management 30/09/2020 PROFIT AND LOSS (€/000) 30/09/2021 30/09/2020 Other revenues Adjustments Adjusted The 3Q 2020 includes an amount of € 1 million for an indemnity related A) REVENUES 49.681 42.347 (1.049) 41.298 to a distribution agreement that has not been renewed fro
Slide 10: Net Revenues
NET REVENUES 50.000 Thousands 40.000 30.000 20.000 10.000 40.684 30/09/2020 Bi italy Rest of world 49,308 30/09/2021 @PHARMANUTRA ®JUNIAPHARMA @ALESCO
Slide 11: Units Sold
u @PHARMANUTRA ®JUNIAPHARMA @ALESCO UNITS SOLD 6.620 Thousands 30/09/2020 30/09/2021 Mitaly mm Rest of World
Slide 12: Iron Supplements SiderAL Market Share in Italy
12 IRON SUPPLEMENTS SIDERAL® MARKET SHARE IN ITALY Excluding products that contain only lactoferrin Source IQVIA
Slide 13: Anti-inflammatory Topical Cream Cetilar Market Share in Italy
13 ANTI-INFLAMMATORY TOPICAL CREAM CETILAR® MARKET SHARE IN ITALY Source IQVIA
Slide 14: Consolidated Balance Sheet
14 CONSOLIDATED BALANCE SHEET ∆ 3Q 21 vs ∆ 3Q 21 vs Amounts in €/000 30/09/2021 31/12/2020 30/09/2020 NET INVESTED CAPITAL FY20 3Q 20 Trade receivables 18.997 15.053 13.636 3.944 5.361 Operating Working Capital Inventories 2.403 1.894 2.076 509 327 The increase of the OWC reflects the increase of th
Slide 15: Consolidated Cash Flow
15 CONSOLIDATED CASH FLOW Cash Flow (€/000) 30/09/2021 31/12/2020 30/09/2020 CASH FROM OPERATING ACTIVITIES Net Result 10.886 14.072 11.414 Amortization, depreciation & write off 2020 includes the write off of the indeminity related to the non NON MONETARY EXPENSES renewal of a distribution agreemen
Slide 16: Net Financial Position Evolution
16 NET FINANCIAL POSITION EVOLUTION NFP The Net Financial Position at 30.09.2021 is € 20.905 million. The cash from operating activities (€ 9.8 million) covers the impact of the dividends paid (€ 6.5 million) and the investing activities (€ 1.6 million).
Slide 17: Outlook 2021
OUTLOOK 2021
Slide 18: Outlook 2021
18 OUTLOOK 2021 • Positive Outlook for 2021 is confirmed: continuous growth of sales on the domestic market, together with the foreign orders backlog, will lead to a medium/high double-digit revenues growth compared to 2020. In addition, potential savings on operative expenses could determine a prof
Slide 19: Pharmanutra
@PHARMANUTRA